ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Aberdeen Group plc

Aberdeen Group plc grew its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 106.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,097,022 shares of the company’s stock after buying an additional 1,594,447 shares during the period. Aberdeen Group plc owned about 3.13% of ARS Pharmaceuticals worth $31,125,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. CWM LLC lifted its stake in ARS Pharmaceuticals by 243.7% during the third quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after purchasing an additional 1,806 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of ARS Pharmaceuticals by 52.8% during the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after purchasing an additional 1,803 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of ARS Pharmaceuticals by 16.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock worth $98,000 after buying an additional 777 shares during the last quarter. RiverPark Advisors LLC acquired a new position in shares of ARS Pharmaceuticals in the 2nd quarter valued at about $100,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of ARS Pharmaceuticals by 58.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock valued at $106,000 after buying an additional 2,245 shares during the period. 68.16% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research downgraded ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 27th. Finally, Roth Mkm began coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective for the company. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.67.

ARS Pharmaceuticals Stock Up 0.5%

Shares of ARS Pharmaceuticals stock opened at $8.85 on Tuesday. The business’s fifty day moving average price is $10.62 and its two-hundred day moving average price is $10.79. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51. The company has a market capitalization of $874.82 million, a P/E ratio of -10.93 and a beta of 0.79. ARS Pharmaceuticals, Inc. has a 1-year low of $6.66 and a 1-year high of $18.90.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.